

Index

Note: Page numbers of article titles are in **boldface** type.

A

- ACCLAIM study. See *Advance Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) study*.
- ACE inhibitors. See *Angiotensin-converting enzyme (ACE) inhibitors*.
- Acute Decompensated Heart Failure National Registry (ADHERE), 24, 114, 115
- Acute heart failure, defined, 110
- Acute Infarction Ramipril Efficacy (AIRE) trial, 33, 74
- Acute myocardial infarction
in patients with left ventricular systolic dysfunction, aldosterone receptor blockade for, **91–105**
sudden cardiac death after, 92–93
- ADHERE. See *Acute Decompensated Heart Failure National Registry (ADHERE)*.
- Adrenergic blockade, comprehensive, for post–myocardial infarction left ventricular dysfunction, **79–89**
- β -Adrenergic receptor variation, in heart failure management, 130–132
- Advance Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) study, 63
- African American Heart Failure Trial (A-HeFT), 61, 117, 118
- Age, as factor in heart failure, 113
diastolic, 27
- AHA/ACC STEMI guidelines, 79
- A-HeFT. See *African American Heart Failure Trial (A-HeFT)*.
- AIRE trial. See *Acute Infarction Ramipril Efficacy (AIRE) trial*.
- Aldosterone, in myocardial infarction, 93–95
- Aldosterone blockade
eplerenone in, 95–97
in chronic heart failure patients, **15–21**
- Aldosterone receptor antagonists, in heart failure management, 61, 130
- Aldosterone receptor blockade, post–myocardial infarction, in patients with left ventricular systolic dysfunction, **91–105**
- Aliskiren Observation of Heart Failure Treatment (ALOFT) Study, 18
- ALOFT Study. See *Aliskiren Observation of Heart Failure Treatment (ALOFT) Study*.
- American College of Cardiology, 65
- American College of Cardiology/American Heart Association and European Society of Cardiology, 15
- American Heart Association, 65, 107
- American Heart Association/American College of Cardiology (AHA/ACC) STEMI guidelines, 79, 84, 85, 87, 100, 102
- Anemia, heart failure and, 66–67
- Angiotensin II–receptor blockers, for diastolic heart failure, 31–32
- Angiotensin receptor antagonists, in post–myocardial infarction patients, **73–77**
- Angiotensin-converting enzyme (ACE) antagonists, in post–myocardial infarction patients, **73–77**
- Angiotensin-converting enzyme (ACE) deletion/insertion polymorphism, 127–130
- Angiotensin-converting enzyme (ACE) inhibitors in asymptomatic left ventricular systolic dysfunction, 5

Angiotensin-converting (*continued*)
 in heart failure, **1–14**, 129–130
 benefit from, patient characteristics as
 determinant of, 9–11
 diastolic, 30–31
 optimal dosing for, 8–9
 post–myocardial infarction, 5
 rationale for, 1–2
 selection of, 8–9
 symptomatic, evidence from critical trials,
 2–4
 in left ventricular systolic dysfunction,
 post–myocardial infarction, 5
 in patients without left ventricular systolic
 dysfunction, heart failure prevention in, 5–8
 neutral endopeptidase inhibition with, in heart
 failure management, 62

Antibody(ies), monoclonal, in heart failure
 management, 63

Anticoagulant(s), in heart failure, **49–52**

Antihypertensive and Lipid-Lowering Treatment
 to Prevent Heart Attack Trial, 30

Antiplatelet(s), in heart failure, **49–52**

Anti-TNF α Therapy Against Chronic Heart
 Failure (ATTACH) phase II study, 63

Assessment of Treatment with Lisinopril and
 Survival (ATLAS) Trial, 9, 50, 60, 129–130

Asymptomatic left ventricular systolic
 dysfunction, ACE inhibitors in, 5

ATLAS Trial. See *Assessment of Treatment with
 Lisinopril and Survival (ATLAS) Trial*.

Atrial fibrillation
 ACE inhibitors for, 30–31
 in diastolic heart failure, 28

ATTACH phase-II study. See *Anti-TNF α Therapy
 Against Chronic Heart Failure (ATTACH) phase
 II study*.

B

BEST. See *Beta-Blocker Evaluation of Survival trial
 (BEST)*.

Beta-Blocker Evaluation of Survival Trial
 (BEST), 53, 60

Beta-Blocker Heart Attach Trial (BHAT), 82, 83

BHAT. See *Beta-Blocker Heart Attach Trial
 (BHAT)*.

β -Blocker(s)

in heart failure management, 128–129
 diastolic, 32–33
 post–myocardial infarction, 81–82
 evidence-based strategy for, 82–87
 implementation of, 87

C

Calcium sensitizers, in heart failure management,
 64–65

Canadian Heart Association, 107

Candesartan in Heart Failure Assessment of
 Reduction in Mortality and Morbidity
 (CHARM)–Added trial, 18, 19, 28, 60–61, 75,
 117

CAPRICORN trial. See *Carvedilol Post-Infarct
 Survival Control in Left Ventricular Dysfunction
 (CAPRICORN) trial*.

Carvedilol Post-Infarct Survival Control in Left
 Ventricular Dysfunction (CAPRICORN) trial,
 82, 83–85, 87

Carvedilol Prospective Randomized Cumulative
 Survival (COPERNICUS) trial, 15, 18

CASINO trial, 65

CASS. See *Coronary Artery Surgery Study (CASS)*.

CDC. See *Centers for Disease Control and
 Prevention (CDC)*.

Centers for Disease Control and Prevention
 (CDC), 113

CHARM–Added trial. See *Candesartan in Heart
 Failure: Assessment of Reduction in Mortality
 and Morbidity (CHARM)–Added trial*.

CHOIR trial. See *Corrections of Hemoglobin and
 Outcomes in Renal Insuficiency (CHOIR) trial*.

Chronic heart failure, aldosterone blockade in,
15–21

Clopidogrel and Metoprolol in Myocardial
 Infarction Trial (COMMIT), 82

COMMIT. See *Clopidogrel and Metoprolol in
 Myocardial Infarction Trial (COMMIT)*.

CONSENSUS II trial. See *Cooperative New
 Scandinavian Enalapril Survival Study II
 (CONSENSUS II) trial*.

Controlled Rosuvastatin Multinational Study in
 Heart Failure (CORONA) trial, 52, 56, 65

Cooperative New Scandinavian Enalapril
 Survival Study II (CONSENSUS II) trial, 74

Download English Version:

<https://daneshyari.com/en/article/2898547>

Download Persian Version:

<https://daneshyari.com/article/2898547>

[Daneshyari.com](https://daneshyari.com)